Yazar "Eker, Ebru Derici" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Evaluation of in vivo DNA damaging and oxidative stress effects of sertraline
    (Elsevier Ireland Ltd, 2013) Aktas, Ayca; Battal, Dilek; Sungur, Mehmet Ali; Yalin, Serap; Kadioglu, Ela; Eker, Ebru Derici; Saygi, Sahan; Aktaş, Ayça; Battal, Dilek; Sungur, Mehmet Ali; Yalın, Serap; Kadıoğlu, Ela; Eker, Ebru Derici; Saygı, Şahan
    Sertraline, SSRI group of medicine, is the most frequently prescribed drug and well-known fact that central nervous system medication. In this study, the potential influence of the therapies with the different doses of sertraline on DNA damaging, lipid peroxidation levels and antioxidant enzyme activities were investigated. For this purpose Male Wistar Albino rats were divided into four group: control (n = 6), low (10 mg/kg/day), moderate (40 mg/kg/day), and high dose (80 mg/kg/day). Each treatment group had 6 animals and sertraline were administered by gavage throughout 28 days of the study. The alkaline comet assay and the cytokinesis-block micronucleus (CBMN) assay were used to evaluate DNA damaging potential of sertraline in the peripheral blood lymphocytes (PBLs). There is no statistically significant difference between sertraline treated groups and the negative control group with respect to comet assay results (p > .05). According to the data obtained from the CBMN test, an increase in the micronucleus (MN) frequency was detected only at high dose sertraline treatment. Serum paroxanase (PON), catalase (CAT), and superoxyde dismutase (SOD) activities were determined as well as malondialdehyde (MDA) lipid peroxidation for evaluation of oxidative stress effects of sertraline treatment. Serum SOD activities showed increase, CAT and PON activities decreased in all groups. Lipid peroxidation levels (MDA) increased in all sertraline treated rats (p < 0.05). Based on the data, it can be concluded that high dose sertraline administration enhances oxidative stress. Therefore, dose adjustment in depression patients seems significant as it may help prevention of further prognosis of the diseases.
  • Küçük Resim
    Öğe
    In Vivo Genotoxicity Assessment of Sertraline by Using Alkaline Comet Assay and the Cytokinesis-Block Micronucleus Assay
    (Wiley, 2013) Battal, Dilek; Aktaş, Ayça; Sungur, Mehmet Ali; Kadıoğlu, Ela; Eker, Ebru Derici; Şahin, Nefise Özlen; Saygi, Şahan
    Sertraline, a leading antidepressant in the selective serotonin reuptake inhibitor (SSRI) group of medicine, is the most frequently prescribed drug. In this study, the alkaline comet assay and the cytokinesis-block micronucleus (CBMN) assay were used to investigate genotoxicity potential of sertraline in the peripheral blood lymphocytes (PBLs) of acute and chronic sertraline-treated Wistar albino rats. Male Wistar albino rats (n=48) were administered low, medium and high doses of sertraline (10, 40, 80mg/kg) for acute and chronic treatment by employing the gavage method to investigate genotoxicity of the administered drug. The data (tail length, tail intensity and tail moment) were analysed and indicated that there was no statistically significant difference between sertraline-treated groups and the negative control group with respect to DNA damage (p>0.05). However, it was observed that acute sertraline administration had caused much more DNA damage in comparison with chronic treatment (p<0.05). According to the data obtained from the CBMN test, an increase in the micronucleus (MN) frequency was detected at chronic and high-dose acute sertraline treatment. Based on the outcome of comet assay, detection of statistically insignificant DNA damage may be due to the fact that sertraline did not cause damage on DNA. Also, increase in frequency of MN in chronic sertraline treatment suggests that chronic sertraline administration might influence some mechanisms of cell division. Therefore, dose adjustment in depressed patients seems significant as it may help prevent further prognosis of the diseases.